Enlivex Therapeutics completes enrollment in Phase II trial of Allocetra

Enlivex Therapeutics announced that the Company completed enrollment of all 120 patients in its Phase II trial of Allocetra in patients with sepsis. The Phase II trial is a placebo-controlled, randomized, dose-finding, multi-country, multi-center study, evaluating frozen-formulation Allocetra in addition to standard of care in patients with sepsis associated with pneumonia, biliary, urinary tract, or peritoneal infections. Sepsis is a life-threatening disease with no therapies approved by the U.S. Food and Drug Administration and a high unmet need. Each year, more than 1.7 million adults in the United States develop sepsis, with annual mortality of more than 270,000 due to the disease.